At a glance
ClinicalIndex Comparison RecordN/ACompleted· 110 enrolled
Drug / intervention
Prasugrel +1 moredrug
Likely dose
Prasugrel 60mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A head-to Head Comparison of the Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease
In Brief
A clinical study evaluating Prasugrel and Ticagrelor for Coronary Artery Disease. Completed, enrolled 110 participants across 1 site.
Detailed Summary
Recently, two P2Y12 receptor inhibitors have been approved for clinical use: prasugrel and ticagrelor. Both prasugrel and ticagrelor have shown to be associated with more potent antiplatelet effects compared with clopidogrel and are associated with an improved net clinical benefit. However, to date there are limited head-to-head comparisons of these two new agents.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2012
First PostedMay 2013
Primary CompletionJun 2014
Study CompletionJul 2014
TodayJul 2026
First PostedMay 13, 2013
Enrollment StartJan 1, 2012
Primary CompletionJun 1, 2014
Study CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 13.1 years ago
Interventions
Prasugreldrug
Prasugrel 60mg loading dose and 10mg maintenance dose
Ticagrelordrug
Ticagrelor 180mg loading dose and 90mg bid maintenance dose